All Blogs
Pivot (invalidation): 1.3075 Our preference Short positions below 1.3075 with targets at 1.3045 & 1.3030 in extension. Alternative scenario...
Pivot (invalidation): 0.9690 Our preference Short positions below 0.9690 with targets at 0.9660 & 0.9640 in extension. Alternative scenario...
Pivot (invalidation): 110.10 Our preference Short positions below 110.10 with targets at 109.80 & 109.60 in extension. Alternative scenario...
Pivot (invalidation): 1.3010 Our preference Long positions above 1.3010 with targets at 1.3035 & 1.3050 in extension. Alternative scenario...
Pivot (invalidation): 1.1120 Our preference Long positions above 1.1120 with targets at 1.1135 & 1.1145 in extension. Alternative scenario...
The pair ended a cycle in wave (1) at .8276 where the 4 is turning up. While above the .8421 lows where the hourly right side is up it can see a bounce correct the cycle from the .9331 highs from 8/12/2019 where the daily is turning down...
Crude is favored ended correcting the cycle up from the 12/24/2018 lows at 51.05 on 10/3/19 where the 4 hour is turning up. The wave (1) cycle from the 10/3/19 lows has ended at 65.68 and while a bounce fails below there expect another swing lower to correct the cycle from the 10/3/19 lows...
Trade Designer TradeBuilderMT5 is an adviser designed to build trading systems based on arbitrary sets of technical indicators. The EA's work is based on the formation and processing of the following signals: OpenBuy / OpenSell - opening positions...
CURRENCY STRENGTH OVERVIEW TODAY CHF continues to be bullish in most timeframes. Make now attention it is overbought in lower timeframes (yellow color for currency strength), pullbacks are likely...
Technology stocks pushed the S&P500 and the Nasdaq to new records on Monday, as the rush toward the equities intensified ahead of the planned signature of the phase one deal between the US and China, and the release of the big US banks’ fourth quarter earnings...
Dare Bioscience Inc. (DARE) shares rose 79% to $1.50 after the company said it is in a licensing agreement with Bayer (BAYN.XE). Bayer may commercialize Dare's investigational contraceptive product Ovaprene in the U.S. once approved by the U.S. Food and Drug Administration, Dare said...
Pivot (invalidation): 58.65 Our preference Short positions below 58.65 with targets at 57.70 & 57.20 in extension. Alternative scenario...
Pivot (invalidation): 13509.00 Our preference Short positions below 13509.00 with targets at 13320.00 & 13273.00 in extension. Alternative scenario...
Pivot (invalidation): 17.9200 Our preference Short positions below 17.9200 with targets at 17.6800 & 17.5300 in extension. Alternative scenario...
Pivot (invalidation): 1548.00 Our preference Short positions below 1548.00 with targets at 1531.00 & 1524.00 in extension. Alternative scenario...
Pivot (invalidation): 3275.00 Our preference Long positions above 3275.00 with targets at 3300.00 & 3309.00 in extension. Alternative scenario...
Pivot (invalidation): 5.8570 Our preference Long positions above 5.8570 with targets at 5.8810 & 5.8950 in extension. Alternative scenario...
Pivot (invalidation): 0.6890 Our preference Long positions above 0.6890 with targets at 0.6910 & 0.6920 in extension. Alternative scenario...
Pivot (invalidation): 1.3065 Our preference Short positions below 1.3065 with targets at 1.3040 & 1.3025 in extension. Alternative scenario...
